Search results

• Karyopharm Announces XPOVIO® (selinexor) Data to be Presented at the 2021 American Society of Clinical Oncology Annual Meeting

  Darrell J., W.

  5/20/21

  2 items of Media coverage

  Press/Media: Research

• Recommended Phase 2 Dose of Selinexor Plus Pomalidomide and Dexamethasone Effective for Relapsed/Refractory Multiple Myeloma

  Darrell J., W.

  12/13/21

  1 item of Media coverage

  Press/Media: Research

• Janssen Announces Health Canada Approval of DARZALEX®* SC, a New Subcutaneous Formulation for the Treatment of Patients with Multiple Myeloma

  Darrell J., W.

  8/5/20

  1 item of Media coverage

  Press/Media: Research

• Nova Scotia Health first in Atlantic Canada to offer cutting-edge cancer treatment, CAR-T cell therapy

  Sudeep Pappur, S. & Darrell J., W.

  6/21/22

  1 item of Media coverage

  Press/Media: Research

• Antengene to Release Preliminary Results of Selinexor for the Treatment of Peripheral T-Cell Lymphoma and NK/T-Cell Lymphoma at the 2021 ASH Annual Meeting

  Darrell J., W.

  11/9/21

  4 items of Media coverage

  Press/Media: Research

• -Karyopharm Announces XPOVIO (selinexor) Data to be Presented at the European Hematology Association 2021 Virtual Congress

  Darrell J., W.

  6/10/21

  1 item of Media coverage

  Press/Media: Research

• Lost to Boston: Nova Scotia-trained doctor says residency red tape forced her to leave

  Darrell J., W.

  1/17/23

  1 item of Media coverage

  Press/Media: Research

• Stigma around renting: housing is a human right whether you rent or buy

  Darrell J., W.

  1/19/23

  1 item of Media coverage

  Press/Media: Research

• Lost to Boston: Nova Scotia-trained doctor says residency red tape forced her to leave

  Darrell J., W.

  1/18/23

  2 items of Media coverage

  Press/Media: Research

• Karyopharm Announces New Interim Phase 2 Selinexor Data in Myelofibrosis Selected for Oral Presentation at the American Society of Hematology 2021 Annual Meeting and Exposition

  Darrell J., W.

  11/4/21

  16 items of Media coverage

  Press/Media: Research

• -Karyopharm Announces New Interim Phase 2 Selinexor Data in Myelofibrosis Selected for Oral Presentation at the American Society of Hematology 2021 Annual Meeting and Exposition

  Darrell J., W.

  11/5/21

  1 item of Media coverage

  Press/Media: Research

• Karyopharm Announces XPOVIO® (Selinexor) Clinical Data To Be Presented At The American Society Of Hematology 2020 Annual Meeting

  Darrell J., W.

  11/4/20

  20 items of Media coverage

  Press/Media: Research

• Karyopharm Announces XPOVIO (selinexor) Data to be Presented at the 2021 American Society of Clinical Oncology Annual Meeting

  Darrell J., W.

  5/19/21

  1 item of Media coverage

  Press/Media: Research

• N.S. offering potentially life-saving cancer treatment so patients don’t have to leave province

  Darrell J., W.

  6/21/22

  1 item of Media coverage

  Press/Media: Research

• Karyopharm Announces XPOVIO® (selinexor) Data to be Presented at the European Hematology Association 2021 Virtual Congress

  Darrell J., W.

  6/9/21

  13 items of Media coverage

  Press/Media: Research

• Karyopharm Announces XPOVIO® (selinexor) Data to be Presented at the 2021 American Society of Clinical Oncology Annual Meeting

  Darrell J., W.

  5/19/21 → 5/20/21

  17 items of Media coverage

  Press/Media: Research

• Karyopharm Announces XPOVIO (selinexor) Data to be Presented at the European Hematology Association 2021 Virtual Congress

  Darrell J., W.

  6/9/21

  1 item of Media coverage

  Press/Media: Research

• Karyopharm Announces XPOVIO (Selinexor) Clinical Data to be Presented at the American Society of Hematology 2020 Annual Meeting

  Darrell J., W.

  11/4/20

  1 item of Media coverage

  Press/Media: Research

• Karyopharm Announces New Interim Phase 2 Selinexor Data in Myelofibrosis Selected for Oral Presentation at the American Society of Hematology 2021 Annual Meeting and Exposition

  Darrell J., W.

  11/3/21

  4 items of Media coverage

  Press/Media: Research

• Janssen Announces Health Canada Approval of DARZALEX®* SC, a New Subcutaneous Formulation for the Treatment of Patients with Multiple Myeloma

  Darrell J., W.

  8/4/20

  2 items of Media coverage

  Press/Media: Research

• Janssen Announces Health Canada Approval of DARZALEX®* SC, a New Subcutaneous Formulation for the Treatment of Patients with Multiple Myeloma

  Darrell J., W.

  8/4/20

  1 item of Media coverage

  Press/Media: Research

• Janssen Announces Health Canada Approval of DARZALEX SC, a New Subcutaneous Formulation for the Treatment of Patients with Multiple Myeloma

  Darrell J., W.

  8/7/20

  1 item of Media coverage

  Press/Media: Research

• Antengene To Release Preliminary Results Of Selinexor For The Treatment Of Peripheral T-Cell Lymphoma And NK/T-Cell Lymphoma At The 2021 ASH Annual Meeting

  Darrell J., W.

  11/9/21

  37 items of Media coverage

  Press/Media: Research